{
    "nctId": "NCT05949333",
    "briefTitle": "Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy",
    "officialTitle": "Reducing Neutropenia Incidence by Changing the Date of Eflapegrastim Administration in Breast Cancer Patients Who Have Experienced Neutropenia After Chemotherapy",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Incidence rate of severe neutropenia Incidence rate of severe neutropenia",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women aged 18 to 75 years old as of the date of study registration.\n* Patients with histologically confirmed invasive adenocarcinoma.\n* Patients with confirmed estrogen receptor, progesterone receptor, and Her2 receptor status.\n* Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n* Patients with a left ventricular ejection fraction (LVEF) \u226555%.\n* Patients who have agreed to participate in this trial and have provided written consent.\n\nExclusion Criteria:\n\n* Patients with a history of breast cancer treatment\n* Patients with a history of chemotherapy, radiation therapy, immunotherapy, or biotherapy for malignancies other than breast cancer\n* Patients with infectious diseases\n* Patients with serious illnesses that may affect this clinical trial: cardiovascular disease, kidney disease, liver disease, endocrine disease, tumors, or diabetes\n* Other individuals deemed by the clinical trial investigators to be unable to participate in the trial.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}